Biocardia, Inc. — Filing Summary
Filing identity: The supplied filing is a Form 10-Q for Tiger X Medical, Inc., formerly Cardo Medical, Inc., not BioCardia, Inc. Verify that this is the intended filing before relying on the figures.
Business context and reporting period
The report covers the quarter ended March 31, 2015. Tiger X had discontinued its former medical-device operations and sold related assets; its continuing revenue came from royalties on product sales by Arthrex. The company also promoted former knee products and evaluated a partner or buyer for remaining intellectual property and potential uses for its cash.
Financial highlights
Amounts are in thousands of dollars, except per-share and share data.
| Metric | Q1 2015 | Q1 2014 or comparison |
|---|---|---|
| Royalty income | $136 | $98; up $38 (about 39%) |
| General and administrative expense | $61 | $35; up $26 |
| Operating income | $75 | $63 |
| Operating margin | About 55% | About 64% |
| Net income | $76 | $64 |
| Operating cash flow | $89 | $27 |
| Cash at period end | $13,598 | $13,509 at Dec. 31, 2014 |
| Total liabilities | $0 | $1 at Dec. 31, 2014 |
| Total assets | $13,620 | $13,545 at Dec. 31, 2014 |
There was no debt outstanding and no investing or financing cash flow during either comparison quarter. The filing presents basic and diluted earnings per share as a dash; it does not provide a clear per-share value. Weighted-average shares were 230,293,141 in both periods.
Changes, outlook, and risks
- Royalty income rose because Arthrex increased sales of the acquired product line. The agreement provides royalties of 5% of net sales, quarterly, for up to 20 years from the 2011 closing.
- Higher professional expenses primarily drove the increase in general and administrative costs. Operating cash flow improved, reflecting higher net income and a favorable change in prepaid expenses and other current assets.
- Management said cash was adequate for needs over the next 12 months and beyond. It expected royalties to remain the primary revenue source absent a transaction involving the remaining intellectual property or a new investment opportunity. No specific earnings or revenue guidance was provided.
- Cash balances exceeded FDIC-insured limits by $13.354 million at March 31, 2015, creating significant bank-deposit concentration risk. Revenue also depended on Arthrex royalties.
- The company reported no material pending legal proceedings, no material changes in internal control, and effective disclosure controls as of March 31, 2015. Management referred readers to risk factors in its 2014 Form 10-K.
Important facts for investors to verify
- Confirm the issuer and filing match the intended BioCardia investment; this report names Tiger X Medical.
- Review the Arthrex agreement, royalty calculations, and the sustainability of sales underlying royalties.
- Assess the uninsured cash concentration and management’s plans for the cash and remaining intellectual property.
- Check the 2014 Form 10-K for the company’s fuller risk disclosures and relevant subsequent developments.